BackIVERIC bio Overview

IVERIC bio Current Cash

Track IVERIC bio's current cash ($470M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$467.57M
143.70% YoYΔ $275.70M vs prior year quarter

Peer average

Loading

IVERIC bio Current Cash History

Loading

IVERIC bio vs. peers: Current Cash Comparison

Loading

IVERIC bio Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

IVERIC bio (ISEE) FAQ

The latest current cash for ISEE is $470M as of March 2023. That compares with $190M in the prior-year period — up 143.7% year over year. Investors often review this figure alongside IVERIC bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, ISEE's current cash moved from $190M to $470M — a 143.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in IVERIC bio's operating scale or balance-sheet position.

A current cash figure of $470M for ISEE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ISEE's current cash ($470M), review year-over-year change from $190M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack IVERIC bio's current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.